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ANTI-INFLAMMATORY LIPID MEDIATOR LIPOXIN A4 PRODUCTION FOL-
LOWING MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Cuvelier, G.D.E., Oleschuk, C., Ellison, C.A., Swajczer, D., Wall, D.A.
CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada
Background: Systemic inflammation results from tissue damage in-
curred from the conditioning regimen and contributes to early post-
allogeneic HSCT complications such as aGVHD. Mechanisms that
actively govern inflammation resolution and dampen exaggerated
inflammatory responses have recently been discovered, but have
not been characterized after allogeneic HSCT. Potent anti-inflam-
matory / pro-resolving eicosanoid lipid mediators play a pivotal
role in this process. Lipoxin A4 (LxA4) is one such lipid mediator
derived from arachidonic acid. In nanomolar concentrations, LxA4
actively inhibits the synthesis and action of a number of Th1 cyto-
kines known to be important in aGVHD, such as TNFa and IL-1.
We wished to determine if and when LxA4 is produced following
allogeneic HSCT.
Methods: Plasma from 16 patients (15-55 years, mean age 37 years)
undergoing allogeneic HSCT was taken at 5 sequential time points
(median, +/2 2 days): Pre-conditioning (day -8), Early 1 (day +4),
Early 2 (day +15), Early 3 (day +28), and Late 1 (day +52). All condi-
tioning regimens were myeloablative and included Bu/Cy (n 5 5),
Bu/Flu/Thymoglobulin +/2 TBI (n 5 5), or Cy/TBI +/2 VP16
or thiotepa (n 5 6). Age and sex-matched healthy volunteers (n 5
16) served as controls. LxA4 was extracted and quantitatively
measured by competitive ELISA according to standard procedures
(Oxford Biomedical).
Results: Plasma LxA4 for controls and patients is presented below
(Table). Bonferoni-corrected t test comparisons between the con-
trol group and each of the 5 time points (Pre-conditioning to Late 1)
identified mean LxA4 concentration in the patients was significantly
higher compared to the control group at all three time points in the
first month after allogeneic HSCT (p\ 0.01). Univariate repeated
measures ANOVA identified a difference in the mean LxA4
concentration in the patients over time from Pre-conditioning until
the Late 1 time point (F 5 2.88, P 5 0.0016).
Conclusions: LxA4 is produced systemically in the first month fol-
lowing myeloablative allogeneic HSCT and peaks approximately
two weeks post-conditioning. Analyses are underway to determine
whether there is a correlation between LxA4 levels and early post-al-
logeneic HSCT complications. This study provides insight into
endogenous mechanisms that may promote the resolution of inflam-
mation post-transplant, and may lead to the development of novel
therapies (e.g. aspirin-triggered lipoxin analogues) aimed at reducing
systemic inflammation.
Table 1. Lipoxin A4 concentrations in plasma.
Pre-Controls Conditioning Early 1 Early 2 Early 3 Late 1Mean Plasma
LxA4 (ng/mL)
0.163 0.274 0.387 * 0.432 * 0.324 * 0.157Standard
Deviation
0.143 0.075 0.182 0.231 0.134 0.074Range
(ng/mL)
0.000-0.525 0.162-0.411 0.147-0.818 0.152-0.934 0.123-0.554 0.110-0.345*p<0.01 versus controls.510
NONINVASIVE PREDICTION OF GRAFT-VERUS-HOST DISEASE FOLLOW-
ING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BY GENE
EXPRESSION PROFILING
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Background: Chronic graft-versus-host disease (cGvHD) and im-
munosuppressive medications for its treatment result in significant
morbidity and mortality, limiting the benefit of allogeneic hemato-
poietic cell transplantation (HCT). A noninvasive, diagnostic andprognostic test is needed to determine which patients have active
cGvHD at present and which subset will have active cGvHD in
the future.
Methods:Weperformed peripheral blood gene expression profiling
to identify transcriptional biomarkers that discriminate active
cGvHD requiring immunosuppression. 63 patients (median age 50
yrs;19-64) following allogeneic HCT (median 475 days post) on an
IRB approved protocol. Samples were randomly selected into a train-
ing set (23 cGvHD/19 without cGvHD) and test set (12 cGvHD/9
without cGvHD) and processed on the Agilent platform. AILUN,
GeneSpring, SAM, and PAM were used to select a minimum gene-
set (FDR \ 5%) to predict cGvHD in the training set. Patient
characteristics in the two groups were collected for confounder/
interaction analysis across the following parameters: age, gender,
disease histology, disease status at HCT, graft source, conditioning
regimen, white blood count (WBC) at sample, and follow-up status
including relapse and survival. Type, grade, and activity of acute
GvHD and cGvHD at time of sample and at most recent follow-
up were determined by two independent investigators by standard
clinical criteria.
Results: There is considerable heterogeneity among cGvHD pa-
tients, not attributable to confounding factors, suggesting molecular
heterogeneity in the development and progression of cGvHD. A
minimum of 10 unique genes selected from SAM and PAM predict
active cGvHD at the time of the sample with 95% sensitivity and
78% specificity in the training set, and 75% sensitivity and 78%
specificity in the test set. Eight and four of ten genes are enriched
in NK and CD4 T cells, respectively, and involved in the IL-10 sig-
naling pathway (p \ 0.01). The 10 gene-set predicted the active
cGvHD at last follow-up (median 849 days post) with 85% sensitiv-
ity and 83% specificity.
Conclusion: Peripheral blood gene-expression across a 10 gene-set
shows strong correlation of the predictive probability of cGvHD.
Given reasonable diagnostic accuracy and sensitivity for prediction
of future cGvHD, additional longitudinal studies of this cohort
and a prospective cohort are underway to further improve the accu-
racy of this approach and predictive power of this gene-set.511
INTEGRIN aV INHIBITION REDUCES GVHD BY TARGETING INFLAMMA-
TORY NEOVASCULARIZATION
Leonhardt, F.1, Behe, M.2, Dumont, R.2, Deininger, F.2, Ruter, B.1,
Durr, C.1, Prinz, G.1, Pfaff, A.-K.1, Finke, J.1, Weber, W.2,
Zeiser, R.1 1Freiburg University Medical Centre, Freburg, Germany;
2Freiburg University Medical Centre, Freiburg, Germany
Integrins are receptors that mediate cell signaling, cell mobility,
extracellular matrix (ECM) interaction and cell cycle regulation.
The integrin avb3 is a receptor that regulates cell adhesion to
ECM, which is a prerequisit for endothelial cells (EC) during vascu-
larization. We therefore hypothesized that the integrin avb3 may be
required for neovascularization as a feature of inflammation and for
the migration of immune cells which both could be relevant during
graft-versus-host (GvHD) development.
By using radionucleotide labeled integrin avb3 ligand and posi-
tron emission tomography (PET) imaging we could demonstrate in-
creased integrin avb3 expression in the gastrointestinal tract (GIT)
following murine allogeneic hematopoietic cell transplantation (al-
loHCT) when GvHD evolved. Pharmacological inhibition of avb3
integrin abrogated the avb3 integrin signal in the GIT detected by
PET. Reduced avb3 integrin expression translated into improved
survival of mice developing GvHD and less severe GvHD histopa-
thology score of the GIT. Also 18F-Fluordesoxyglucose-PET dem-
onstrated a lower signal intensity in the GIT when pharmacological
inhibition of integrin avb3 was applied, indicative for reduce inflam-
matory activity. Although we observed increased integrin av expres-
sion on donor T cells, the protective effect of integrin av inhibition
was not dependent on lower donor T cell proliferation or abnormal
migration as assessed with bioluminescence imaging. Histological
analysis demonstrated inflammatory neovascularization in the GIT
tissue in BMT recipients that developed GvHD.
These data indicate that avb3 integrin is a novel target to interfere
with GvHDbased on inhibition of inflammatory neovascularization.
